10 Firms Lead Rally on Impressive Q1 Earnings, Optimistic Outlooks

2. Hims & Hers Health, Inc. (NYSE:HIMS)

Hims & Hers saw its share prices jump by 9.24 percent on Thursday to end at $36.16 apiece as investors repositioned portfolios ahead of the release of its earnings performance next week.

According to a statement, Hims & Hers Health, Inc. (NYSE:HIMS) will announce its earnings results after the market closes on Monday, May 5, 2025, where investors will be closely watching out for the company’s updated outlook guidance for the rest of the year.

In recent news, Hims & Hers Health, Inc. (NYSE:HIMS) clinched a long-term deal with Novo Nordisk to jointly market the latter’s blockbuster weight loss drug, Wegovy.

Hims & Hers Health, Inc. (NYSE:HIMS) said that Americans can now access NovoCare Pharmacy directly through its platform, with a bundled offering of all dose strengths of Wegovy and a Hims & Hers membership, including access to 24/7 care, ongoing clinical support, and nutrition guidance, among others.

It can be learned that HIMS used to make a compounded knock-off version of the treatment that helped propel its sales over the past few years. It was later discontinued after the Food and Drug Administration announced that Novo Nordisk had already produced a sufficient supply of the treatment.